HALO - Halozyme Therapeutics - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40637H1095
Enzymes, Devices, Injectables, Biologics, Therapies
Halozyme Therapeutics Inc. is a biopharma technology platform company that develops and commercializes innovative enzymes and devices to improve the delivery of injectable biologics and other therapeutic molecules. The company's proprietary technology is based on a patented recombinant human hyaluronidase enzyme (rHuPH20), which enables the delivery of a wide range of medications, including monoclonal antibodies, small molecules, and fluids, through subcutaneous injection.
The company's product portfolio includes Hylenex recombinant, which facilitates subcutaneous fluid administration for hydration and enhances the dispersion and absorption of other injected drugs. Additionally, Halozyme offers a range of medications for various indications, including HIV, multiple sclerosis, testosterone replacement therapy, and cancer treatment. These products include rilpivirine, cabotegravir, and N6LS BNAB for HIV treatment, ocrelizumab for multiple sclerosis, and XYOSTED for testosterone replacement therapy.
Halozyme also provides several medications for cancer treatment, including Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo for breast cancer, as well as Mabthera SC for chronic lymphocytic leukemia. Furthermore, the company offers HYQVIA for primary immunodeficiency disorders and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma.
In addition to its proprietary products, Halozyme also partners with other pharmaceutical companies to develop and commercialize new medications. The company's pipeline includes several promising candidates, such as Epinephrine Injection for allergic reactions, nivolumab+relatlimab and ANTI-TIM3 for solid tumors, and ARGX-117 for multifocal motor neuropathy.
Halozyme Therapeutics Inc. was founded in 1998 and is headquartered in San Diego, California. With a strong focus on innovation and collaboration, the company is committed to improving patient outcomes and advancing the field of biopharma technology.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
HALO Stock Overview
Market Cap in USD | 6,714m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2004-03-16 |
HALO Stock Ratings
Growth 5y | 73.7 |
Fundamental | 85.2 |
Dividend | |
Rel. Performance vs Sector | 0.22 |
Analysts | 3.82/5 |
Fair Price Momentum | 52.24 USD |
Fair Price DCF | 80.41 USD |
HALO Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
HALO Growth Ratios
Growth Correlation 3m | -42.7% |
Growth Correlation 12m | 86.1% |
Growth Correlation 5y | 53.7% |
CAGR 5y | 26.90% |
CAGR/Mean DD 5y | 1.46 |
Sharpe Ratio 12m | 1.12 |
Alpha vs SP500 12m | 4.41 |
Beta vs SP500 5y weekly | 1.06 |
ValueRay RSI | 6.86 |
Volatility GJR Garch 1y | 36.31% |
Price / SMA 50 | -12.58% |
Price / SMA 200 | 6.21% |
Current Volume | 1167.5k |
Average Volume 20d | 1378.7k |
External Links for HALO Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 29, 2024, the stock is trading at USD 50.46 with a total of 1,167,540 shares traded.
Over the past week, the price has changed by -2.53%, over one month by -11.43%, over three months by -9.03% and over the past year by +48.98%.
According to ValueRays Forecast Model, HALO Halozyme Therapeutics will be worth about 57.3 in October 2025. The stock is currently trading at 50.46. This means that the stock has a potential upside of +13.59%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 61.7 | 22.3 |
Analysts Target Price | 51.9 | 2.85 |
ValueRay Target Price | 57.3 | 13.6 |